Production (Stage)
Addex Therapeutics Ltd
ADXN
$8.40
$0.192.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 458.40K | 630.00K | 938.90K | 1.51M | 1.79M |
| Total Other Revenue | 6.80K | 7.40K | 3.90K | 5.10K | 4.70K |
| Total Revenue | 465.40K | 637.60K | 942.80K | 1.52M | 1.79M |
| Cost of Revenue | 965.30K | 1.06M | 1.38M | 1.33M | 1.32M |
| Gross Profit | -500.00K | -421.80K | -435.60K | 189.70K | 468.00K |
| SG&A Expenses | 2.62M | 3.02M | 3.13M | 3.20M | 2.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.59M | 4.08M | 4.51M | 4.53M | 4.30M |
| Operating Income | -3.12M | -3.44M | -3.57M | -3.01M | -2.51M |
| Income Before Tax | -5.57M | -5.23M | -4.27M | -3.24M | -2.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.57 | -5.23 | -4.27 | -3.24 | -2.80 |
| Earnings from Discontinued Operations | 13.14M | 10.95M | 8.79M | -9.46M | -8.97M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.57M | 5.72M | 4.52M | -12.70M | -11.77M |
| EBIT | -3.12M | -3.44M | -3.57M | -3.01M | -2.51M |
| EBITDA | -2.91M | -3.25M | -3.43M | -3.00M | -2.50M |
| EPS Basic | 0.08 | 0.05 | 0.03 | -0.15 | -0.16 |
| Normalized Basic EPS | -0.04 | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | 0.07 | 0.05 | 0.03 | -0.16 | -0.16 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 392.48M | 380.47M | 359.45M | 333.33M | 297.05M |
| Average Diluted Shares Outstanding | 462.16M | 450.16M | 429.14M | 333.33M | 297.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |